Shafeek BUHLAK

Dr. Shafeek BUHLAK

Faculty of pharmacy, Pharmaceutical Department, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul Aydın University, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2023 in Heliyon
Verified
Journal Article
Open access
NANadeem Abad
Nadeem Abad
Fares Hezam Al-OstootFares Hezam Al-Ostoot
Fares Hezam Al-Ostoot
SASajda Ashraf
Sajda Ashraf
KCKarim Chkirate
Karim Chkirate
MAMajed S. Aljohani
Majed S. Aljohani
YRYoussef Ramli
Youssef Ramli
Overall, drug design is a dynamic and evolving field, with researchers constantly working to improve their understanding of molecular interactions, develop new computational methods, and explore innovative techniques for creating effective and safe medications. The process can involve steps such as the identification of targets, the discovery of lead compounds, lead optimization, preliminary testing, human trials, regulatory approval and finally post-marketing surveillance, all aimed at bringing a new drug from concept to market. In this article, the synthesis of the novel triazolequinoxalin (TZQ) 1-((1-hexyl-1H-1,2,3-triazol-5-yl)methyl)-3-phenylquinoxalin-2(1H)-one (4) is reported. The structure has been identified with a variety of spectroscopic methods (1H, 13C NMR, and LC-MS) and finally, the structure has been determined by X-ray diffraction (XRD) studies. The TZQ molecule has crystallized in the monoclinic space C2/c group with unit cell dimensions a = 41.201(2) Å, b = 10.6339(6) Å, c = 9.4997(4) Å, β = 93.904(4). The crystal structure is stabilized by intermolecular interactions (N–H ⋯ O and N–H … Cg) occurring within the molecule. The presence of these intermolecular interactions is evaluated through analysis of Hirshfeld surfaces (HS) and two-dimensional (2D) chemical fingerprints map. Additionally, energy frameworks were employed to identify the prevailing interaction energy influencing the molecular arrangement. Density Functional Theory (DFT) calculations were computed to establish concurrence between theoretical and experimental results. Furthermore, the HOMO-LUMO energy levels were determined using the B3LYP/6-31+G(d, p) level of theory. Finally, molecular docking was used to predict the anti-cancer activity of the compound (4) against PFKFB3 kinase and presented noticeable hydrophilic and hydrophobic interactions at the active site region.

18 April 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
NANadeem Abad
Nadeem Abad
Shafeek BUHLAKShafeek BUHLAK
Shafeek BUHLAK
Melek HajjiMelek Hajji
Melek Hajji
SSSana Saffour
Sana Saffour
JAJihane Akachar
Jihane Akachar
AMAdil Mardinoglu
Adil Mardinoglu

8 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Shafeek BUHLAKShafeek BUHLAK
Shafeek BUHLAK
NANadeem Abad
Nadeem Abad
JAJihane Akachar
Jihane Akachar
SSSana Saffour
Sana Saffour
YKYunus Kesgun
Yunus Kesgun
AMAdil Mardinoglu
Adil Mardinoglu
Background/Objectives: Glioblastoma multiforme (GBM), an aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment due to its resistance to current therapies and poor prognosis. This study aimed to synthesise and evaluate 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, designed to enhance druggability and solubility, and to investigate their potential as VEGFR2 inhibitors for GBM treatment. Methods: The synthesised compounds were analysed using in silico methods, including molecular docking and dynamics studies, to assess their interactions with key residues within the VEGFR2 binding pocket. In vitro evaluations were performed on U87-MG and U138-MG GBM cell lines using MTT assays to determine the IC50 values of the compounds. Results: Among the tested compounds, 4u (IC50 = 7.96 μM), 4t (IC50 = 10.48 μM), 4m (IC50 = 4.20 μM), and 4q (IC50 = 8.00 μM) demonstrated significant antiproliferative effects against both the U87-MG and U138-MG cell lines. These compounds exhibited markedly higher efficacy compared to temozolomide (TMZ), which showed IC50 values of 92.90 μM and 93.09 μM for U87-MG and U138-MG, respectively. Molecular docking and dynamics studies confirmed strong interactions between the compounds and VEGFR2 kinase, supporting their substantial anti-cancer activity. Conclusions: This study highlights the promising potential of 3,4-dihydroquinolin-2(1H)-one analogues, particularly 4m, 4q, 4t, and 4u, as VEGFR2-targeting therapeutic agents for GBM treatment. Further detailed research is warranted to validate and expand upon these findings.

9 August 2024 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
Shafeek BUHLAKShafeek BUHLAK
Shafeek BUHLAK
NANadeem Abad
Nadeem Abad
JAJihane Akachar
Jihane Akachar
SSSana Saffour
Sana Saffour
YKYunus Kesgun
Yunus Kesgun
AMAdil Mardinoglu
Adil Mardinoglu
Glioblastoma multiforme (GBM), an exceptionally aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment. The rapid progression of GBM and the difficulty of achieving drug penetration through the blood-brain barrier (BBB) hinder current therapeutic approaches. This highlights the critical need for developing new and potent medications specifically targeting GBM. This study focuses on the synthesis of 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, integrating enhanced druggable features and solubilizing entities. In silico-analyses provided insight into the inhibitory effects of these compounds, highlighting interactions with essential residues within the target's VEGFR2 binding pocket. In vitro evaluations conducted on two different GBM cell lines (U87-MG) and (U138-MG), compounds 4u (IC50=7.96 µM), 4t (IC50=10.48 µM) and 4m (IC50=4.20 µM), 4q (IC50=8.00 µM) demonstrated significant efficacy, respectively. These analogues markedly reduced the viability of both U87-MG and U138-MG GBM cells compared with temozolomide (TMZ) (IC50=92.90 µM /U87-MG and 93.09 µM /U138-MG). Molecular docking studies and dynamics focusing on VEGFR2 Kinase, a key factor in GBM pathogenesis, showed that our 3,4-dihydroquinolin-2(1H)-one analogues possess substantial anti-cancer activity against GBM cells. Our results emphasize the notable anti-cancer potential of the novel 3,4-dihydroquinolin-2(1H)-one analogues, especially 4m, 4q, 4t, and 4u, against GBM. We advocate for further detailed research to confirm and investigate the therapeutic value of these promising compounds.

31 December 2025 in European Journal of Chemistry
Verified
Journal Article
Open access
PDF file
DÖDevrim Özdemirhan
Devrim Özdemirhan
Shafeek BUHLAKShafeek BUHLAK
Shafeek BUHLAK
DKDurukan Koç
Durukan Koç
As herein defined; a ring closing metathesis (RCM) reaction of N-anchored homoallylic dienes followed by enzymatic kinetic resolution and ring closing enyne metathesis (RCEM) with an intramolecular Pauson-Khand reaction of N-tethered homopropargylic enynes are described for the first time. RCM afforded azaspirodeca and -undecadiene with 78 and 82% chemical yields, as well as azaspironona and decadienecarboxylates with 65 and 70% chemical yields, respectively. Furthermore, RCEM protocol resulted in conjugated diene 50% chemical yield. Moreover, intramolecular Pauson-Khand reaction is also applied to enynes, which yielded cyclopenta[c]pyrrole-carboxylate as diastereomeric mixtures; besides cyclopenta[c]pyridin-one and cyclopenta[c]pyridin-carboxylate frameworks as single diastereomers. Above all, secondary amines (azaspirodeca and undecadiene) have been efficiently resolved through an enzyme-catalyzed reaction in a moderate ee up to 77 and 20% ee, with their corresponding esters up to 75 and 55% ee, in the presence of CAL-B (being the most effective biocatalyst) and recombinant from Aspergillus oryzae. Both CAL-B and CAL-A-CLEA afforded reverse enantiomeric separation of them for the first time.

16 June 2026 in Structural Chemistry
Verified
Journal Article
Closed access
Shafeek BUHLAKShafeek BUHLAK
Shafeek BUHLAK
MHMelek Hajji
Melek Hajji
INIntissar Nchioua
Intissar Nchioua
JMJoel T. Mague
Joel T. Mague
HAHanan Al‑Ghulikah
Hanan Al‑Ghulikah
NANadeem Abad
Nadeem Abad